NCT05882383

Brief Summary

To explore whether cornea structure, and optical quality are affected by the covid-19 infection.

Trial Health

87
On Track

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Enrollment
110

participants targeted

Target at P50-P75 for all trials

Timeline
Completed

Started Nov 2022

Shorter than P25 for all trials

Geographic Reach
1 country

1 active site

Status
completed

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

Study Start

First participant enrolled

November 25, 2022

Completed
2 months until next milestone

Primary Completion

Last participant's last visit for primary outcome

January 20, 2023

Completed
Same day until next milestone

Study Completion

Last participant's last visit for all outcomes

January 20, 2023

Completed
4 months until next milestone

First Submitted

Initial submission to the registry

May 8, 2023

Completed
23 days until next milestone

First Posted

Study publicly available on registry

May 31, 2023

Completed
Last Updated

May 31, 2023

Status Verified

May 1, 2023

Enrollment Period

2 months

First QC Date

May 8, 2023

Last Update Submit

May 27, 2023

Conditions

Corneal Wavefront AberrationSARS-CoV-2

Keywords

optical quality

Outcome Measures

Primary Outcomes (3)

  • The value of cornea aberration

    The value of aberration data from pentacam during follow-up were compared, including coma, spherical aberration, defocus, and astigmatism

    1 months

  • The value of cornea backscatter

    The value of cornea backscatter from pentacam during follow-up were compared, including anterior layer，central layer and posterior

    1 months

  • The value of cornea thickness

    The value of cornea thickness from pentacam during follow-up were compared, includig the thinnest point, apex of the cornea.

    1 months

Study Arms (3)

Control Group

unifected with SARS-CoV-2 during follow-up

Group A

uninfected at the first visit, have been infected at the second visit

group B

have been infected at twice visit

Eligibility Criteria

Age18 Years - 32 Years
Sexall
Healthy VolunteersYes
Age GroupsAdult (18-64)
Sampling MethodNon-Probability Sample
Study Population

patients admitted to refractive center of Tianjin Eye Hospital

You may not qualify if:

  • corneal disease;
  • ocular trauma;
  • Pregnant and lactating women;

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (1)

Tianjin Eye Hospital

Tianjin, Tianjin Municipality, China

Location

MeSH Terms

Conditions

Corneal Wavefront Aberration

Condition Hierarchy (Ancestors)

Corneal DiseasesEye DiseasesRefractive Errors

Study Officials

  • Yan Wang, Prof

    Tianjin eye hosipital

    STUDY CHAIR

Study Design

Study Type
observational
Observational Model
COHORT
Time Perspective
CROSS SECTIONAL
Sponsor Type
OTHER
Responsible Party
SPONSOR

Study Record Dates

First Submitted

May 8, 2023

First Posted

May 31, 2023

Study Start

November 25, 2022

Primary Completion

January 20, 2023

Study Completion

January 20, 2023

Last Updated

May 31, 2023

Record last verified: 2023-05

Locations

CN(1)